BR112022020884A2 - Processos de enriquecimento de vesículas extracelulares (evs) específicas e de processo de identificação de vesículas extracelulares, processo para determinar um tratamento para um paciente com câncer e kit - Google Patents

Processos de enriquecimento de vesículas extracelulares (evs) específicas e de processo de identificação de vesículas extracelulares, processo para determinar um tratamento para um paciente com câncer e kit

Info

Publication number
BR112022020884A2
BR112022020884A2 BR112022020884A BR112022020884A BR112022020884A2 BR 112022020884 A2 BR112022020884 A2 BR 112022020884A2 BR 112022020884 A BR112022020884 A BR 112022020884A BR 112022020884 A BR112022020884 A BR 112022020884A BR 112022020884 A2 BR112022020884 A2 BR 112022020884A2
Authority
BR
Brazil
Prior art keywords
extracellular vesicles
evs
enrichment
cancer
kit
Prior art date
Application number
BR112022020884A
Other languages
English (en)
Inventor
J Lowe Christopher
Plaks Vicki
M Ruppel Jane
Suttmann Rebecca
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112022020884A2 publication Critical patent/BR112022020884A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROCESSOS DE ENRIQUECIMENTO DE VESÍCULAS EXTRACELULARES (EVS) ESPECÍFICAS E DE PROCESSO DE IDENTIFICAÇÃO DE VESÍCULAS EXTRACELULARES, PROCESSO PARA DETERMINAR UM TRATAMENTO PARA UM PACIENTE COM CÂNCER E KIT. A invenção fornece métodos para enriquecer vesículas extracelulares (EVs), incluindo exossomos, de amostras de fluido biológico de indivíduos e, opcionalmente, testar ainda mais os EVs quanto à presença de biomarcadores específicos.
BR112022020884A 2020-04-17 2021-04-16 Processos de enriquecimento de vesículas extracelulares (evs) específicas e de processo de identificação de vesículas extracelulares, processo para determinar um tratamento para um paciente com câncer e kit BR112022020884A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011583P 2020-04-17 2020-04-17
PCT/US2021/027627 WO2021211935A1 (en) 2020-04-17 2021-04-16 Methods for enriching extracellular vesicles from biological fluid samples

Publications (1)

Publication Number Publication Date
BR112022020884A2 true BR112022020884A2 (pt) 2022-11-29

Family

ID=75919381

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020884A BR112022020884A2 (pt) 2020-04-17 2021-04-16 Processos de enriquecimento de vesículas extracelulares (evs) específicas e de processo de identificação de vesículas extracelulares, processo para determinar um tratamento para um paciente com câncer e kit

Country Status (13)

Country Link
US (1) US20230204588A1 (pt)
EP (1) EP4136451A1 (pt)
JP (1) JP2023522003A (pt)
KR (1) KR20230004496A (pt)
CN (1) CN115427810A (pt)
AR (1) AR122422A1 (pt)
AU (1) AU2021257455A1 (pt)
BR (1) BR112022020884A2 (pt)
CA (1) CA3178835A1 (pt)
IL (1) IL297284A (pt)
MX (1) MX2022012824A (pt)
TW (1) TW202204896A (pt)
WO (1) WO2021211935A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114073865B (zh) * 2022-01-17 2022-11-25 深圳市达科为生物工程有限公司 去除血清中外泌体的方法及过滤装置
WO2023196586A1 (en) * 2022-04-07 2023-10-12 The Regents Of The University Of Michigan Methods and devices for screening extracellular vesicles
CN117153252B (zh) * 2023-08-31 2024-08-16 山东第一医科大学附属省立医院(山东省立医院) 一种用于弥漫大b细胞淋巴瘤患者预后生物标志物及其系统和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140141986A1 (en) * 2011-02-22 2014-05-22 David Spetzler Circulating biomarkers
US10874610B2 (en) * 2016-10-19 2020-12-29 Northwestern University Extracellular vesicle-based diagnostics and engineered exosomes for targeted therapeutics against cancer
WO2019014486A1 (en) * 2017-07-12 2019-01-17 Exosome Diagnostics, Inc. METHODS FOR ISOLATING AND ENRICHING POPULATIONS OF EXTRACELLULAR VESICLES DERIVED FROM BIOFLUIDS, AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
MX2022012824A (es) 2022-11-07
CA3178835A1 (en) 2021-10-21
TW202204896A (zh) 2022-02-01
EP4136451A1 (en) 2023-02-22
JP2023522003A (ja) 2023-05-26
CN115427810A (zh) 2022-12-02
KR20230004496A (ko) 2023-01-06
IL297284A (en) 2022-12-01
AR122422A1 (es) 2022-09-07
WO2021211935A1 (en) 2021-10-21
AU2021257455A1 (en) 2022-10-20
US20230204588A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
BR112022020884A2 (pt) Processos de enriquecimento de vesículas extracelulares (evs) específicas e de processo de identificação de vesículas extracelulares, processo para determinar um tratamento para um paciente com câncer e kit
Kirschner et al. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
BR112018009071A2 (pt) método para preparar uma amostra, composição homogenizada, métodos para gerar dados, para tratar uma doença, de identificação de um marcador, para determinar o prognóstico de um câncer, para determinar um perfil fenotípico, para armazenar a composição homogenizada, para preparar uma amostra de tecido e preparar a composição homogenizada
BR112019006004A2 (pt) método e sistema para criação de um intervalo de referência personalizado, e, método para analisar associações clínicas.
BR112016029521A2 (pt) ?kit, dispositivo e método para a detecção de câncer de estômago?
NZ749272A (en) Phospholipid ether analogs for the identification and isolation of circulating tumor cells
Ma et al. Serum GRP78 as a tumor marker and its prognostic significance in non‐small cell lung cancers: a retrospective study
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
WO2013040502A3 (en) Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder
CO2019002607A2 (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activación por contacto
BR112019005172A2 (pt) método e kit para analisar uma amostra
ES2845150T3 (es) Diagnóstico de pancreatitis aguda (PA) mediante la detección de glicoproteína 2 isoforma alfa (GP2A)
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
BR112022007386A2 (pt) Métodos para tratar um câncer hematológico e o uso de biomarcadores companheiros para 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona
BR112021012352A2 (pt) Ensaio multiplexado e seus métodos de uso
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
BR112022000322A2 (pt) Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer
BR112023001045A2 (pt) Métodos para clivar um anticorpo e analisar a sequência de um anticorpo, composição e kit para digestão de uma proteína
BR112019025079A2 (pt) Biossensores eletroquímicos
CO2019002599A2 (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto
BR112019007138A2 (pt) método e sistema de análise para testagem de uma amostra
BR112018076005A2 (pt) anticorpo monoclonal isolado, método para medir o nível de gama-glutamil-l-epsilon-lisina (ggel), método ex vivo para o monitoramento de apoptose, uso de um anticorpo monoclonal específico para gama-glutamil-l-epsilon-lisina (ggel), métodos para monitorar a eficácia de um tratamento indutor de apoptose, método de tratamento de uma doença associada a apoptose desregulada, kit para o monitoramento de apoptose, método de tratamento de sepse e dispositivo de imunoensaio de fluxo lateral
RU2009109664A (ru) Способ выявления и определения происхождения неизвестных веществ в биологических жидкостях пациентов, принимавших наркотические или психоактивные вещества
BR112021023254A2 (pt) Métodos relacionados à tuberculose
Li et al. P3. 09-03 Alteration of Gut Microbiome in Lung Cancer Patients